Dirk Schadendorf, MD, Head of Department for Dermatology, Venerology und Allergology, University Hospital Essen, Germany, discusses the results from the phase III CheckMate 067 study, which looked at a combination immunotherapy regimen in advanced melanoma.
Conferences
Dr. Omid Hamid on Vemurafenib and Atezolizumab in Melanoma
Omid Hamid, MD, Chief, Translational Research and Immunotherapy, Director, Melanoma Therapeutics, The Angeles Clinic, discusses a recent trial investigating the combination of vemurafenib and atezolizumab in melanoma in patients with previously untreated BRAF-positive unresectable or metastatic melanoma.
The targeted therapy vemurafenib has a great initial response rate and palliative benefit, but does not have long-term durability. Atezolizumab, an immunotherapy, has a low initial response rate, but has the ability to have a high long-term durability, says Hamid.
Epacadostat/Pembrolizumab Combo Shows Activity in Advanced Melanoma
A novel combination immunotherapy regimen of epacadostat plus pembrolizumab shows promising clinical activity and is generally well-tolerated by advanced melanoma patients, according to a new study presented at the Society for Melanoma Research 2015 International Congress, held November 18–21 in San Francisco.
Cobimetinib/Vemurafenib Improves Survival in BRAF-Mutated Melanoma
combination of cobimetinib and vemurafenib prolongs overall survival (OS) in melanoma patients with BRAF V600 mutations, according to a new study presented at the Society for Melanoma Research 2015 International Congress, held November 18–21 in San Francisco.